Anti-HIV IgA isotypes: Differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission

AIDS

Volumn 27, Issue 9, 2013, Pages

  Watkins, Jennifer D ^a,b   Sholukh, Anton M ^a,b   Mukhtar, Muhammad M ^a,b   Siddappa, Nagadenahalli B ^a,b,f   Lakhashe, Samir K ^a,b   Kim, Mikyung ^a,b   Reinherz, Ellis L ^a,b   Gupta, Sandeep ^c   Forthal, Donald N ^c   Sattentau, Quentin J ^d   Villinger, Francois ^e,f   Corti, Davide ^g   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e EMORY UNIVERSITY   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Humabs SAGL ^*  (Switzerland)

Author keywords

HIV neutralization; Immunoglobulin A isotypes; Mucosal transmission; R5 SHIV; Transcytosis; Virion capture

Indexed keywords

DIMERIC IMMUNOGLOBULIN A1 ANTIBODY; DIMERIC IMMUNOGLOBULIN A2 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCYTOSIS; VIRION; VIRUS LOAD; VIRUS TRANSMISSION;

ADMINISTRATION, RECTAL; AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A; INTESTINAL MUCOSA; MACACA MULATTA; NEUTRALIZATION TESTS; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCYTOSIS; VIRAL LOAD; VIRION;

EID: 84879122811     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328360eac6     Document Type: Article

References (22)

1. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
2. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
3. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
4. Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 2011; 6:e18207.
5. Kramer VG, Siddappa NB, Ruprecht RM. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 2007; 5:642-655.
6. Bonner A, Furtado PB, Almogren A, Kerr MA, Perkins SJ. Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy. J Immunol 2008; 180:1008-1018.
7. Bonner A, Almogren A, Furtado PB, Kerr MA, Perkins SJ. The nonplanar secretory IgA2 and near planar secretory IgA1 solution structures rationalize their different mucosal immune responses. J Biol Chem 2009; 284:5077-5087.
8. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-1920.
9. Choi RY, Levinson P, Guthrie BL, Payne B, Bosire R, Liu AY, et al. Cervicovaginal HIV-1 neutralizing IgA detected among HIV-1-exposed seronegative female partners in HIV-1-discordant Kenyan couples. AIDS 2012; 26:2155-2163.
10. Hasselrot K, Saberg P, Hirbod T, Soderlund J, Ehnlund M, Bratt G, et al. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 2009; 23:329-333.
11. Mantis NJ, Palaia J, Hessell AJ, Mehta S, Zhu Z, Corthesy B, et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 2007; 179:3144-3152.
12. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269-280.
13. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
14. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5:e8805.
15. Rasmussen RA, Ong H, Kittel C, Ruprecht CR, Ferrantelli F, Hu SL, et al. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Vaccine 2006; 24:2324-2332.
16. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005 [Chapter 12: Unit 12.11]. doi:10.1002/0471142735.im1211s64
17. Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, et al. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One 2010; 5:e11689.
18. Hofmann-Lehmann R, Swenerton RK, Liska V, Leutenegger CM, Lutz H, McClure HM, et al. Sensitive and robust one-tube realtime reverse transcriptase- polymerase chain reaction to quantify SIV RNA load: comparison of oneversus two-enzyme systems. AIDS Res Hum Retroviruses 2000; 16:1247-1257.
19. Cline AN, Bess JW, Piatak M Jr, Lifson JD. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 2005; 34:303-312.
20. Chomont N, Hocini H, Gody JC, Bouhlal H, Becquart P, Krief-Bouillet C, et al. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology 2008; 370:246-254.
21. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441:847-852.
22. Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, Schwartz-Cornil I, et al. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A 2012; 109:12680-12685.